Evidence map›Paper›PMID 39339263›Full record

ArticlePharmaceutics2024

Development of Biolayer Interferometry (BLI)-Based Double-Stranded RNA Detection Method with Application in mRNA-Based Therapeutics and Vaccines.

Dharia Sara Silas, Bindiya Juneja, Keerat Kaur, Muralikrishna Narayanareddy Gari, Yingjian You, Youmi Moon, Yizhuo Chen, Srishti Arora, Johanna Hansen, Kathir Muthusamy and 3 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Chemical Modifications in Nucleic Acid Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dharia Sara SilasProtein Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Bindiya JunejaProtein Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Keerat KaurRegeneron Genetic Medicines, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Muralikrishna Narayanareddy GariVaccine Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Yingjian YouVaccine Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Youmi MoonProtein Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Yizhuo ChenRegeneron Genetic Medicines, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Srishti AroraRegeneron Genetic Medicines, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Johanna HansenVaccine Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Kathir MuthusamyProtein Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Yue FuProtein Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
Nisha PalackalProtein Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.ORCID 0009-0004-7449-8953
Erica A PylesProtein Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

binding affinitybiolayer interferometry (BLI)double stranded RNA (dsRNA)FHV B2RNA detection methodsuridine modification

Identifiers

PMID39339263
PMCPMC11435032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.